Verastem, Inc. 10-Q Summary
Business Context and Reporting Period
Verastem is a development-stage biopharmaceutical company focused on small-molecule cancer stem-cell therapies and companion diagnostics. The filing covers the three and six months ended June 30, 2012. The company had not generated revenue and remained focused on research, preclinical development, licensing and preparation for future clinical programs.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2012 | Six Months Ended June 30, 2012 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $4.7 million | $9.5 million |
| General and administrative expense | $2.2 million | $4.3 million |
| Total operating expenses | $6.9 million | $13.8 million |
| Net loss | $6.8 million | $13.7 million |
| Net loss per share | $0.34 | $0.79 |
| Net cash used in operating activities | Not separately provided | $9.9 million |
At June 30, 2012, cash and cash equivalents were $15.8 million, short-term investments were $22.9 million, and long-term investments were $65.6 million, for total cash, cash equivalents and investments of approximately $104.3 million. Total assets were $105.7 million, current liabilities were $3.2 million, and no debt balance was disclosed. The company reported a development-stage accumulated deficit of $28.2 million.
There were no meaningful operating margins because the company had no revenue and all operations were loss-making. Stock-based compensation was $3.0 million for the six months ended June 30, 2012. Interest income was $128,000 for the six-month period.
Material Changes Versus Prior Comparable Period
- Six-month research and development expense increased to $9.5 million from $2.4 million, primarily because of higher personnel costs, outsourced research and development, license-related expense, laboratory supplies and facility costs.
- Six-month general and administrative expense increased to $4.3 million from $1.2 million, driven by higher personnel costs, public-company legal and accounting fees, consulting and insurance expenses.
- Six-month net loss increased to $13.7 million from $3.6 million; quarterly net loss increased to $6.8 million from $2.5 million.
- Cash used in operating activities increased to $9.9 million from $1.0 million for the first six months of 2011.
- The February 2012 initial public offering raised $56.8 million of net proceeds. All preferred stock converted into common stock, and the company’s common shares outstanding increased materially.
- Investments increased substantially as IPO proceeds were placed into government-sponsored enterprise securities and government-secured commercial paper.
Guidance, Outlook, Risks and Unusual Items
- Management expected existing cash, cash equivalents and investments to fund the current operating plan and capital expenditure requirements into late 2015 or early 2016, subject to current estimates and spending levels.
- The company expected significant increases in research and development, clinical development, regulatory, commercialization and public-company expenses, and anticipated continuing operating losses.
- Management stated that substantial additional funding would eventually be required; additional financing might not be available on acceptable terms or at all.
- On May 11, 2012, the company acquired PI3K/mTOR inhibitor compounds and related patent rights from S*Bio for $350,000, recorded as research and development expense. Additional milestone payments of up to approximately $21.0 million and low- to mid-single-digit royalties may become payable.
- On July 11, 2012, after quarter-end, the company licensed worldwide exclusive rights to certain Pfizer focal adhesion kinase inhibitors. Consideration included $1.5 million in cash and 192,012 common shares. Pfizer may receive up to $127.0 million in development, regulatory and commercial milestones, plus high-single- to mid-double-digit royalties on future net sales.
- The company had no material legal proceedings, no off-balance-sheet arrangements and no material changes to previously disclosed risk factors.
- Principal risks included the need for additional capital, clinical and regulatory uncertainty, dependence on third parties, intellectual-property protection, competition, potential inability to develop commercially valuable products and continuing losses.
Important Facts for Investors to Verify
- Whether the projected cash runway through late 2015 or early 2016 remains achievable as research and clinical spending increases.
- The development status, clinical milestones and funding requirements for VS-507, VS-4718, VS-5095 and the acquired Pfizer and S*Bio programs.
- The potential dilution from equity compensation, the Pfizer share issuance and future capital raises.
- The probability and timing of milestone payments and the economic impact of future royalty obligations.
- Whether the company can obtain regulatory approvals and ultimately generate commercial revenue; the filing provides no assurance that it will do so.